Investors / filer profile

Bienaime Jean Jacques

active in 4 companies · 1 of 1 positions beat the S&P ~6mo later

Pro
Bought: Pro
Sold: 13
Filings: 4
Companies: 2026-08-14
Last filed

EDGAR · CIK 0001221590 ↗

Track record

How each disclosed position did against the S&P ~6 months later

The outcome curve and every position's resultPro →

+100.1%

median move per position

+10.6%

S&P 500 median, same spans

1 of 1

beat the S&P ~6mo later

3 positions still inside the ~6-month window — not scored yet.

Disclosed positions

Estimated from their latest filings — positions may have changed since

Estimated positions from their latest filingsPro →

Activity

Open-market buy & sell volume

BuySell

Total +$857.9K bought · −$203.8K sold

All filings on record

Every Form 4 transaction we track for this filer


ASNDAscendis Pharma A/S	Buy $222.2K · 900 sh	2026-08-14	—
ASNDAscendis Pharma A/S	Buy $270.4K · 1,100 sh	2026-08-14	—
IMNMImmunome Inc.	Buy $19.3K · 1,000 sh	2026-06-05	—
IMNMImmunome Inc.	Buy $68.1K · 3,500 sh	2026-06-05	—
IMNMImmunome Inc.	Buy $116.9K · 6,000 sh	2026-06-05	—
IMNMImmunome Inc.	Sell $194.1K · 10,000 sh	2026-06-05	—
IMNMImmunome Inc.	Sell $9.7K · 500 sh	2026-06-05	—
KROSKeros Therapeutics, Inc.	Grant — · 7,142 sh	2026-06-03	—
KROSKeros Therapeutics, Inc.	Buy $10.6K · 1,000 sh	2026-05-15	—
IMNMImmunome Inc.	Buy $103.5K · 5,000 sh	2026-05-15	—

ASNDBuy

2026-08-14 · Ascendis Pharma A/S

$222.2K

—

ASNDBuy

2026-08-14 · Ascendis Pharma A/S

$270.4K

—

IMNMBuy

2026-06-05 · Immunome Inc.

$19.3K

—

IMNMBuy

2026-06-05 · Immunome Inc.

$68.1K

—

IMNMBuy

2026-06-05 · Immunome Inc.

$116.9K

—

IMNMSell

2026-06-05 · Immunome Inc.

$194.1K

—

IMNMSell

2026-06-05 · Immunome Inc.

$9.7K

—

KROSGrant

2026-06-03 · Keros Therapeutics, Inc.

7,142

—

KROSBuy

2026-05-15 · Keros Therapeutics, Inc.

$10.6K

—

IMNMBuy

2026-05-15 · Immunome Inc.

$103.5K

—

Newest 10 of 13 filingsEvery Form 4 on record, with outcomesPro →

Outcomes measure each position — the first buy in a stock and every buy within 182 days — against the closing price ~6 months (120 trading days) later, with the S&P 500 over the same span for context. Pre-scheduled 10b5-1 plan trades are excluded from the record. Positions are estimated from the latest reported post-transaction holdings, split-adjusted, at the latest close. Built from SEC Form 4 filings and market prices — past outcomes, not predictions or advice.